These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1792648)

  • 21. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Basic requirements for the use of terms for reporting adverse drug reactions (VIII): renal and urinary system disorders.
    Council for International Organizations of Medical Sciences
    Pharmacoepidemiol Drug Saf; 1997 May; 6(3):203-11. PubMed ID: 15073789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Definitions of terms for reporting adverse drug reactions (IX): nervous system and psychiatric disorders.
    Council for International Organizations of Medical Sciences
    Pharmacoepidemiol Drug Saf; 1998 Jan; 7(1):39-49. PubMed ID: 15073745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Adverse drug reactions definitions and terminology].
    Rabinovitz H; Berkowitch M; Golik A; Shani S
    Harefuah; 2001 Dec; 140(12):1181-6, 1228. PubMed ID: 11789305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. European drug agency criticises Roche for failing to report adverse reactions and patient deaths.
    Wise J
    BMJ; 2012 Jun; 344():e4344. PubMed ID: 22736470
    [No Abstract]   [Full Text] [Related]  

  • 27. International monitoring for adverse drug reactions of long latency.
    Fletcher AP; Griffin JP
    Adverse Drug React Toxicol Rev; 1991; 10(4):209-30. PubMed ID: 1793771
    [No Abstract]   [Full Text] [Related]  

  • 28. The management of adverse drug reactions: from diagnosis to signal.
    Edwards IR
    Therapie; 2001; 56(6):727-33. PubMed ID: 11878098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishing requirements for the use of terms for reporting adverse drug reactions.
    Venulet J
    Int J Clin Pharmacol Res; 1992; 12(2):61-4. PubMed ID: 1428299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
    Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
    Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulatory decisions and consumers.
    Rawlins MD
    Med Toxicol; 1986; 1 Suppl 1():128-9. PubMed ID: 3821428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience.
    Blenkinsopp A; Wilkie P; Wang M; Routledge PA
    Br J Clin Pharmacol; 2007 Feb; 63(2):148-56. PubMed ID: 17274788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 34. Points of view on adverse drug reactions terminology.
    Benichou C; Castle W
    Therapie; 1998; 53(2):145-9. PubMed ID: 9773114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse drug reaction reporting. Philippine experience.
    Ines Cuyegkeng E
    Med Toxicol; 1986; 1 Suppl 1():99-104. PubMed ID: 3821435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Provision of information on regulatory authorities' websites.
    Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
    Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of a database computer program to identify trends in reporting of adverse drug reactions.
    Johnston PE; Morrow JD; Branch RA
    Am J Hosp Pharm; 1990 Jun; 47(6):1321-7. PubMed ID: 2368725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Program coordinated by a drug information service to improve adverse drug reaction reporting in a hospital.
    Michel DJ; Knodel LC
    Am J Hosp Pharm; 1986 Sep; 43(9):2202-5. PubMed ID: 3766573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality assurance through adverse drug reaction reporting: improving hypnotic prescribing.
    Phillips MS
    Hosp Pharm; 1990 Mar; 25(3):246-8. PubMed ID: 10170509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Evaluation of medication side-effects from an economic perspective].
    Segura O; Maldonado C
    Biomedica; 2003 Dec; 23(4):401-7. PubMed ID: 14968918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.